form
solution
Application
Positive control for immunoblotting techniques. A streak of M.W. > 116 kDa is detected by immunoblotting, representing PARP modified to various extents by poly(ADP-ribose). Recommended use: 5-20 μl per gel lane.
Other Notes
Partially purified bovine PARP, automodified by the addition of NAD and necessary cofactors.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
signalword
Danger
Hazard Classifications
Acute Tox. 4 Dermal - Aquatic Chronic 3 - Eye Dam. 1 - Repr. 2 - Skin Sens. 1
Storage Class
10 - Combustible liquids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Related Content
Datasheet
Carla O Contreras-Ochoa et al.
Experimental parasitology, 134(2), 256-265 (2013-03-30)
Toxoplasma gondii invades any nucleated cell, but different replication speed and effects on survival/apoptosis processes have been found depending on cell type. There are scarce and controversial results regarding the effect of this parasite on host cell apoptosis within the
Karen L Cooper et al.
Toxicology and applied pharmacology, 269(2), 81-88 (2013-03-26)
Arsenic is a recognized human carcinogen and there is evidence that arsenic augments the carcinogenicity of DNA damaging agents such as ultraviolet radiation (UVR) thereby acting as a co-carcinogen. Inhibition of DNA repair is one proposed mechanism to account for
Wan Zhao et al.
Cancer chemotherapy and pharmacology, 71(5), 1287-1295 (2013-03-13)
Platinum-based chemotherapy is the most common treatment for patients with advanced non-small cell lung cancer (NSCLC). Genetic polymorphisms in the base excision repair (BER) pathway are suspected to influence the response of patients to this type of therapy. In this


